ReviewMaterials (Basel, Switzerland)2024
Nanostructured Medical Devices: Regulatory Perspective and Current Applications.
Review in Materials (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- From Bench to Bone: Translational Pathways of Nanomaterial-Based Therapies in Craniomaxillomandibulofacial and Cranial Vault Reconstruction.Bioengineering (Basel, Switzerland) · 2026Review
- Reimagining Spinal Surgery at the Nanoscale: Smart Implants, Targeted Therapies, and Translational Challenges.Biology · 2026Review
- Are Silver and Gold Nanoparticles Obtained by 'Green' Synthesis Biocompatible?Nanomaterials (Basel, Switzerland) · 2026Review
- Biogenic Selenium Nanoparticles Functionalized with Natural Polymers or Phytochemicals for Targeted Disruption ofJournal of functional biomaterials · 2026Review
- Nanomaterial-enabled smart contact lenses: bridging sensing, therapy, and theranostics for next-generation ocular healthcare.Journal of nanobiotechnology · 2026Review
- Nanomaterial-enabled delivery of plant-derived bioactive metabolites for diabetic retinopathy: from evidence appraisal to preclinical translation.Frontiers in pharmacology · 2026Review
- Application of Amorphous Nanomaterials in Dentistry: A Comprehensive Review.Journal of functional biomaterials · 2025Review
- Thermally Conductive Biopolymers in Regenerative Medicine and Oncology: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Photothermal Combination Therapy for Metastatic Breast Cancer: A New Strategy and Future Perspectives.Biomedicines · 2025Review
- From innovation to application: safety concerns in nanomaterial implant coatings.Nanomedicine (London, England) · 2025Article
- Nanotechnology-Based Therapies for Preventing Post-Surgical Adhesions.Pharmaceutics · 2025Review
- Layer-by-Layer Nanoarchitectonics: A Method for Everything in Layered Structures.Materials (Basel, Switzerland) · 2025Review
- Advances in nanomaterials for precision drug delivery: Insights into pharmacokinetics and toxicity.BioImpacts : BI · 2025Review
- Nanotechnology in Orthopedic Care: Advances in Drug Delivery, Implants, and Biocompatibility Considerations.International journal of nanomedicine · 2025Review
- Materials Nanoarchitectonics for Advanced Devices.Materials (Basel, Switzerland) · 2024Review
- Magnesium-Titanium Alloys: A Promising Solution for Biodegradable Biomedical Implants.Materials (Basel, Switzerland) · 2024Review
- Liquid-Liquid and Liquid-Solid Interfacial Nanoarchitectonics.Molecules (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomaterials (NMs) are having a huge impact in several domains, including the fabrication of medical devices (MDs). Hence, nanostructured MDs are becoming quite common; nevertheless, the associated risks must be carefully considered in order to demonstrate safety prior to their immission on the market. The biological effect of NMs requires the consideration of methodological issues since already established methods for, e.g., cytotoxicity can be subject to a loss of accuracy in the presence of certain NMs. The need for oversight of MDs containing NMs is reflected by the European Regulation 2017/745 on MDs, which states that MDs incorporating or consisting of NMs are in class III, at highest risk, unless the NM is encapsulated or bound in such a manner that the potential for its internal exposure is low or negligible (Rule 19). This study addresses the role of NMs in medical devices, highlighting the current applications and considering the regulatory requirements of such products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.